Top Medical News
Audrey Abella, Yesterday
The addition of abobotulinumtoxinA (aboBTX-A) – one of three commercial preparations of botulinum toxin (BTX) type A – to phosphodiesterase type 5 inhibitors (PDE5-Is) or prostaglandin E1 (PGE1) led to favourable outcomes in men with erectile dysfunction (ED), a new study shows.
Audrey Abella, 2 days ago
Ketorolac, a non-steroidal anti-inflammatory drug (NSAID) and cyclooxygenase inhibitor, is effective and safe in preventing catheter-related bladder discomfort (CRBD) in men who have undergone robot-assisted laparoscopic radical prostatectomy (RALP), highlighting its potential role in postoperative CRBD management, a study shows.
Audrey Abella, 3 days ago
Use of the novel penile traction therapy (PTT) device, RestoreX, in combination with injections of collagenase Clostridium histolyticum (CCH), led to significant improvements in penile deformities due to Peyronie’s disease (PD), a study has shown.
Audrey Abella, 5 days ago
The alpha-1 blocker naftopidil facilitated spontaneous expulsion of small ureteral stones in men, highlighting its potential in medical expulsive therapy (MET) for individuals with ureteral stones, a Japanese study has shown.
6 days ago
There appears to be an association between low muscle mass and increased risks of recurrence and mortality in patients who undergo radical prostatectomy of prostate cancer regardless of the body mass index (BMI), suggests a recent study.
17 Aug 2019
A recent study has shown that hyperbaric oxygen therapy can improve graft take in staged tubularized autograft reoperations for hypospadias.
17 Aug 2019
Robot-assisted radical prostatectomy offers superior outcomes over the laparoscopic technique for patients who underwent previous bladder outlet surgery of benign prostatic hyperplasia, according to a systematic review and pooled analysis of comparative studies.
Special Reports
15 Mar 2019
At the Eisai-sponsored tea symposium during the 27th Malaysian Urological Conference at Shangri-La Kuala Lumpur, Professor Osamu Yokoyama highlighted the advantages of silodosin (Urief®, Eisai Inc.) in relieving lower urinary tract symptoms associated with benign prostate hyperplasia.
02 Nov 2017
Nocturia is the most prevalent of the lower urinary tract symptoms (LUTS) and can cause a significant negative impact on an individual’s quality of life if left untreated.1,2 In a meeting held at University Malaya Medical Centre, Associate Professor Dr Ong Teng Aik shared his insights on the management of nocturia.
Conference Reports
Jackey Suen, 06 Mar 2019

The future of poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors in the treatment of metastatic castration-resistant prostate cancer (mCRPC) is promising in light of encouraging results from recent clinical studies.

Dr. Joseph Delano Fule Robles, 04 Mar 2019

Since the approval of immune checkpoint inhibitors (ICIs) as standard of care in the second-line setting for metastatic urothelial carcinoma, new approaches on how clinicians manage this condition are emerging.

Dr. Joseph Delano Fule Robles, 22 Feb 2019

Studies have demonstrated that robot-assisted radical cystectomy (RARC) is as effective and has a cost advantage compared with open cystectomy for the management of urologic cancers.

Jackey Suen, 30 Jan 2019

Recent research has revealed various potential biomarkers for metastatic castration-resistant prostate cancer (mCRPC), but several challenges remain in fully utilizing them in clinical practice.

Audrey Abella, 11 May 2018
Nanotechnology structured water was similarly effective as tadalafil in improving erectile function, suggesting that it could be a potential treatment option for erectile dysfunction (ED), according to a study presented at EAU held in Copenhagen, Denmark.
Audrey Abella, 30 Apr 2018
The selective β3-adrenoreceptor (AR) agonist vibegron showed superior efficacy over placebo for overactive bladder (OAB) treatment and was generally well-tolerated, according to a Japanese study presented at EAU 2018.

Roshini Claire Anthony, 23 Apr 2018

Targeted antibiotic prophylaxis – after a rectal swab to identify specific intestinal flora – does not appear to significantly impact the risk of urinary sepsis following a transrectal ultrasound (TRUS)-guided prostate biopsy, according to a recent study.